Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.

Abstract

Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function.

• Authors: F Milat, S Goh, L U Gani, C Suriadi, M T Gillespie, P J Fuller, H J Teede, A H Strickland, C A Allan
• Journal: Bone (Bone) Vol. 55 Issue 2 Pg. 305-8 (Aug 2013) ISSN: 1873-2763 [Electronic] United States
• PMID: 23685544 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Crown Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents
• Denosumab

Topics

• Aged
• Antibodies, Monoclonal, Humanized (adverse effects)
• Bone Density Conservation Agents (adverse effects)
• Bone Neoplasms (drug therapy, secondary)
• Denosumab
• Humans
• Hypocalcemia (chemically induced)
• Male
• Prostatic Neoplasms (drug therapy, pathology)